Barclays PLC Buys New Stake in Inhibikase Therapeutics, Inc. (NYSE:IKT)
Barclays PLC bought a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 84,000 shares of the company’s stock, valued at approximately $273,000. A number of other institutional investors and hedge […]
Barclays PLC bought a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 84,000 shares of the company’s stock, valued at approximately $273,000. A number of other institutional investors and hedge […]
